These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18992382)

  • 21. Evolution of the health economics of cervical cancer vaccination.
    Ferko N; Postma M; Gallivan S; Kruzikas D; Drummond M
    Vaccine; 2008 Sep; 26 Suppl 5():F3-15. PubMed ID: 18992381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
    Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N
    Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
    Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
    Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
    Wong G; Howard K; Webster A; Chapman JR; Craig JC
    Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Public health issues related to HPV vaccination.
    Hershey JH; Velez LF
    J Public Health Manag Pract; 2009; 15(5):384-92. PubMed ID: 19704306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean.
    Franco EL; Tsu V; Herrero R; Lazcano-Ponce E; Hildesheim A; Muñoz N; Murillo R; Sánchez GI; Andrus JK
    Vaccine; 2008 Aug; 26 Suppl 11():L88-95. PubMed ID: 18945406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of cervical cancer: where immunology meets diagnostics.
    Meijer CJ; Heideman DA; Berkhof H; Snijders PJ
    Immunol Lett; 2009 Feb; 122(2):126-7. PubMed ID: 19100775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling.
    Goldie SJ; Goldhaber-Fiebert JD; Garnett GP
    Vaccine; 2006 Aug; 24 Suppl 3():S3/155-63. PubMed ID: 16950003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus vaccine: a paradigm shift for pediatricians.
    Jenson HB
    Curr Opin Pediatr; 2009 Feb; 21(1):112-21. PubMed ID: 19242247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
    Rogoza RM; Westra TA; Ferko N; Tamminga JJ; Drummond MF; Daemen T; Wilschut JC; Postma MJ
    Vaccine; 2009 Jul; 27(35):4776-83. PubMed ID: 19539578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ; O'Shea M; Diaz M; Kim SY
    Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural differences among cost-effectiveness models of human papillomavirus vaccines.
    Insinga RP; Dasbach EJ; Elbasha EH
    Expert Rev Vaccines; 2008 Sep; 7(7):895-913. PubMed ID: 18767941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding HPV disease and prevention: a guide for school nurses.
    Lockwood-Rayermann S; McIntyre SJ
    J Sch Nurs; 2009 Aug; 25(4):261-9. PubMed ID: 19363106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-benefit analysis on the HPV vaccine in Medicaid-enrolled females of the Appalachian region of Kentucky.
    Prasad SR; Hill R
    J Ky Med Assoc; 2008 Jun; 106(6):271-6. PubMed ID: 18630037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of human papillomavirus vaccination in developed countries.
    Brisson M; Van de Velde N; Boily MC
    Public Health Genomics; 2009; 12(5-6):343-51. PubMed ID: 19684446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of cervical cancer.
    Denny L
    Reprod Health Matters; 2008 Nov; 16(32):18-31. PubMed ID: 19027619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Introduction of vaccination against human papillomavirus in developing countries: update and perspectives].
    Hessel L
    Med Trop (Mars); 2009 Aug; 69(4):323-6. PubMed ID: 19725378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination against human papillomavirus.
    BMJ Group
    Drug Ther Bull; 2008 Dec; 46(12):89-93. PubMed ID: 19056700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mathematical models of cervical cancer prevention in Latin America and the Caribbean.
    Goldie SJ; Diaz M; Constenla D; Alvis N; Andrus JK; Kim SY
    Vaccine; 2008 Aug; 26 Suppl 11():L59-72. PubMed ID: 18945403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Making the case for cervical cancer prevention: what about equity?
    Tsu VD; Levin CE
    Reprod Health Matters; 2008 Nov; 16(32):104-12. PubMed ID: 19027628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.